|
KMID : 0388220100170030246
|
|
Journal of the Korean Rheumatism Association
2010 Volume.17 No. 3 p.246 ~ p.253
|
|
|
The Incidence of Serious Infection among Rheumatoid Arthritis Patients Exposed to Tumor Necrosis Factor Antagonists
|
|
Kim Hyun-Ok
Kang Kwi-Young
Ju Ji-Hyeon
Kim Ho-Youn
Park Sung-Hwan
|
|
|
Abstract
|
|
|
Objective: We wanted to investigate the incidence of serious infections among the rheumatoid arthritis (RA) patients who were treated with tumor necrosis factor ? (TNF-?) antagonists
Methods: We enrolled the 175 RA patients who were treated with TNF-? antagonists for at least 3 months during February 2003 to July 2008, and these patients were in the SMART-b cohort of Kangnam St. Mary’s hospital. Patients were prescribed infliximab, etanercept or adalimumab. The data was retrospectively collected.
Results: The incidence of serious infections among the RA patients treated with TNF-? was significantly increased according to the survival analysis, as compared with that of those patient treated with conventional DMARDs (p＜0.01). The most common serious infection was pneumonia. There was no significant difference in the incidence of serious infections among the three TNF-? antagonists used in this study (p=0.96). But the serious infections occurred more often in the patients who received more than 10 mg methotrexate (MTX) per week (p=0.02).
Conclusion: RA patients treated with TNF-? antagonists had a higher incidence of serious infection. Therefore, close monitoring for serious infection is needed for RA patients who are receiving TNF-? antagonists.
|
|
|
KEYWORD
|
|
|
Rheumatoid arthritis, Serious infection, TNF-? antagonists
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|